PDF herunterladen
Augenheilkunde up2date 2020; 10(01): 8-16
DOI: 10.1055/a-0646-6404
Handlungspfade
Georg Thieme Verlag KG Stuttgart · New York

Mykotische Keratitis: Klinische Zeichen, Diagnose, Therapie

Mathias Roth‡
,
Friedrich Steindor‡
,
Oliver Kurzai
,
Wolfgang Behrens-Baumann
,
Colin R. Mackenzie
,
Gerd Geerling
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
05. Februar 2020 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Ein erhabenes Infiltrat, Satellitenherde und ein pyramidenförmiges Hypopyon sind nahezu pathognomonisch für eine mykotische Keratitis. Dieser typische Befund ist in solcher Eindeutigkeit jedoch selten, meist wird die korrekte Diagnose spät gestellt. Insbesondere bei fortgeschrittenen Befunden kann es zu einem Verlust des Auges kommen. Aus diesem Grund empfehlen wir eine zügige und aggressive Therapie, die entsprechend des Verlaufs aktiv angepasst wird.
 

  • Literatur

  • 1 Gower EW, Keay LJ, Oechsler RA. et al. Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology 2010; 117: 2263-2267
    CrossrefPubMedGoogle Scholar
  • 2 Tuli SS, Iyer SA, Driebe WT. Fungal keratitis and contact lenses: An old enemy unrecognized or a new nemesis on the block?. Eye Contact Lens 2007; 33: 415-417
    CrossrefPubMedGoogle Scholar
  • 3 Roth M, Daas L, Renner-Wilde A. et al. Das Deutsche Pilz-Keratitis-Register. Ophthalmologe 2019; 116: 957-966 doi:10.1007/s00347-019-0871-9
    CrossrefPubMedGoogle Scholar
  • 4 Dahlgren MA, Lingappan A, Wilhelmus KR. The clinical diagnosis of microbial keratitis. Am J Ophthalmol 2007; 143: 940-944
    CrossrefPubMedGoogle Scholar
  • 5 Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003–2005. Eye (Lond) 2009; 23: 1308-1313
    CrossrefPubMedGoogle Scholar
  • 6 Nielsen SE, Nielsen E, Julian HO. et al. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol 2015; 93: 54-58
    CrossrefPubMedGoogle Scholar
  • 7 Behrens-Baumann W. Zur klinischen Diagnose der Pilzkeratitis. Z prakt Augenheilkd 2010; 31: 577-580
    Google Scholar
  • 8 Behrens-Baumann W, Finis D, MacKenzie C. et al. Keratomykose – Therapiestandards und aktuelle Entwicklungen. Klin Monatsbl Augenheilkd 2015; 232: 754-764
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Roth M, Schrader S, Finis D. et al. Diagnostik von Binde- und Hornhauterkrankungen: Teil 2: Diagnostik infektiöser Hornhaut- und Bindehauterkrankungen. Klin Monatsbl Augenheilkd 2015; 232: 789-806
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Kheirkhah A, Syed ZA, Satitpitakul V. et al. Sensitivity and Specificity of Laser-Scanning In Vivo Confocal Microscopy for Filamentous Fungal Keratitis: Role of Observer Experience. Am J Ophthalmol 2017; 179: 81-89
    CrossrefPubMedGoogle Scholar
  • 11 Das S, Sharma S, Kar S. et al. Is inclusion of Sabouraud dextrose agar essential for the laboratory diagnosis of fungal keratitis?. Indian J Ophthalmol 2010; 58: 281-286
    CrossrefPubMedGoogle Scholar
  • 12 Thomas PA, Teresa PA, Theodore J. et al. PCR for the molecular diagnosis of mycotic keratitis. Expert Rev Mol Diagn 2012; 12: 703-718
    CrossrefPubMedGoogle Scholar
  • 13 Bharathi MJ, Ramakrishnan R, Meenakshi R. et al. Microbiological diagnosis of infective keratitis: comparative evaluation of direct microscopy and culture results. Br J Ophthalmol 2006; 90: 1271-1276
    CrossrefPubMedGoogle Scholar
  • 14 Al-Badriyeh D, Leung L, Roydhouse T. et al. Prospective open-label study of the administration of two-percent voriconazole eye drops. Antimicrob Agents Chemother 2009; 53: 3153-3155
    CrossrefPubMedGoogle Scholar
  • 15 Martin MJ, Rahman MR, Johnson GJ et al. Mycotic keratitis: Susceptibility to antiseptic agents. Int Ophthalmol 1995; 19: 299-302
    CrossrefPubMedGoogle Scholar
  • 16 Rahman MR, Johnson GJ, Husain R. et al. Randomised trial of 0.2 % chlorhexidine gluconate and 2.5 % natamycin for fungal keratitis in Bangladesh. Br J Ophthalmol 1998; 82: 919-925
    CrossrefPubMedGoogle Scholar
  • 17 Prajna NV, Krishnan T, Mascarenhas J. et al. The mycotic ulcer treatment trial. JAMA Ophthalmol 2013; 131: 422-429
    CrossrefPubMedGoogle Scholar
  • 18 Sharma S, Das S, Virdi A. et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol 2015; 99: 1190-1195
    CrossrefPubMedGoogle Scholar
  • 19 Guidelines for the Management of corneal Ulcer at primary, secondary & tertiary Care Health Facilities in the South-East Asia Region. New Delhi: World Health Organization Regional Office for South-East; 2004
    Google Scholar
  • 20 Sharma N, Sahay P, Maharana PK. et al. Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol. Cornea 2019; 38: 141-145
    CrossrefPubMedGoogle Scholar
  • 21 Bourcier T, Sauer A, Dory A. et al. [Fungal keratitis]. J Fr Ophtalmol 2017; 40: 882-888
    CrossrefPubMedGoogle Scholar
  • 22 FlorCruz NV, Peczon I, Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2015; (02) CD004241
    PubMedGoogle Scholar
  • 23 Sradhanjali S, Yein B, Sharma S. et al. In vitro synergy of natamycin and voriconazole against clinical isolates of Fusarium, Candida, Aspergillus and Curvularia spp. Br J Ophthalmol 2018; 102: 142-145
    CrossrefPubMedGoogle Scholar
  • 24 Sharma N, Chacko J, Velpandian T. et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Ophthalmology 2013; 120: 677-681
    CrossrefPubMedGoogle Scholar
  • 25 Prajna NV, Mascarenhas J, Krishnan T. et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol 2010; 128: 672-678
    CrossrefPubMedGoogle Scholar
  • 26 Prajna NV, Krishnan T, Rajaraman R. et al. Effect of oral voriconazole on fungal keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II) a randomized clinical trial. JAMA Ophthalmol 2016; 134: 1365-1372
    CrossrefPubMedGoogle Scholar
  • 27 Titiyal JS, Velpandian T, Maharana PK. et al. Comparison of Oral Voriconazole Versus Oral Ketoconazole as an Adjunct to Topical Natamycin in Severe Fungal Keratitis. Cornea 2017; 36: 1521-1527
    CrossrefPubMedGoogle Scholar
  • 28 Niki M, Eguchi H, Hayashi Y. et al. Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis. Clin Ophthalmol 2014; 8: 1075
    PubMedGoogle Scholar
  • 29 Prakash G, Sharma N, Goel M. et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008; 146: 56-59
    CrossrefPubMedGoogle Scholar
  • 30 Kalaiselvi G, Narayana S, Krishnan T. et al. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 2015; 99: 195-198
    CrossrefPubMedGoogle Scholar
  • 31 Sharma N, Agarwal P, Sinha R. et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: Case series. Br J Ophthalmol 2011; 95: 1735-1737
    CrossrefPubMedGoogle Scholar
  • 32 Narayana S, Krishnan T, Ramakrishnan S. et al. Mycotic Antimicrobial Localized Injection (MALIN): A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole. Ophthalmology 2019; 126: 1084-1089 doi:10.1016/j.ophtha.2019.03.020
    CrossrefPubMedGoogle Scholar
  • 33 Tu EY, Majmudar PA. Adjuvant stromal amphotericin B injection for late-onset DMEK infection. Cornea 2017; 36: 1556-1558
    CrossrefPubMedGoogle Scholar
  • 34 Garcia-Valenzuela E, Song CD. Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis. Arch Ophthalmol 2005; 123: 1721-1723
    CrossrefPubMedGoogle Scholar
  • 35 Sahay P, Singhal D, Nagpal R. et al. Pharmacologic therapy of mycotic keratitis. Surv Ophthalmol 2019; 64: 380-400 doi:10.1016/j.survophthal.2019.02.007
    CrossrefPubMedGoogle Scholar
  • 36 Bell RW, Ritchey JP. Subconjunctival nodules after amphotericin B injection. Medical therapy for Aspergillus corneal ulcer. Arch Ophthalmol 1973; 90: 402-404
    CrossrefPubMedGoogle Scholar
  • 37 Kaji Y, Yamamoto E, Hiraoka T. et al. Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B. Graefeʼs Arch Clin Exp Ophthalmol 2009; 247: 549-553
    PubMedGoogle Scholar
  • 38 Carrasco MA, Genesoni G. Treatment of severe fungal keratitis with subconjunctival amphotericin B. Cornea 2011; 30: 608-611
    CrossrefPubMedGoogle Scholar
  • 39 Pate JC, Jones DB, Wilhelmus KR. Prevalence and spectrum of bacterial co-infection during fungal keratitis. Br J Ophthalmol 2006; 90: 289-292
    CrossrefPubMedGoogle Scholar
  • 40 Matoba AY, Divatia MK, Arguello RA. et al. Clinically Significant Enhancement of Voriconazole Efficacy by Moxifloxacin and Gentamicin in Fungal Keratitis. Cornea 2018; 37: 651-654
    CrossrefPubMedGoogle Scholar
  • 41 Green K, Bowman K, Hull DS. Chlorhexidine Effects on Epithelium and Endothelium. Arch Ophthalmol 1980; 98: 1273-1278
    CrossrefPubMedGoogle Scholar
  • 42 Panda A, Ahuja R, Biswas NR. et al. Role of 0.02% polyhexamethylene biguanide and 1% povidone iodine in experimental Aspergillus keratitis. Cornea 2003; 22: 138-141
    CrossrefPubMedGoogle Scholar
  • 43 Behrens-Baumann W, Seibold M, Hofmüller W. et al. Benefit of polyhexamethylene biguanide in Fusarium keratitis. Ophthalmic Res 2012; 48: 171-176
    CrossrefPubMedGoogle Scholar
  • 44 Fiscella RG, Moshifar M, Messick CR. et al. Polyhexamethylene biguanide (PHMB) in the treatment of experimental Fusarium keratomycosis. Cornea 1997; 16: 447-449
    PubMedGoogle Scholar
  • 45 Rebong RA, Santaella RM, Goldhagen BE. et al. Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. Investig Ophthalmol Vis Sci 2011; 52: 7309-7315
    CrossrefPubMedGoogle Scholar
  • 46 Raghavan A, Baidwal S, Venkatapathy N. et al. The Acanthamoeba-Fungal keratitis study. Am J Ophthalmol 2019; 201: 31-36 doi:10.1016/j.ajo.2019.01.024
    CrossrefPubMedGoogle Scholar
  • 47 Rosetta P, Legrottaglie EF, Pagano L. et al. Corneal Cross-Linking Window Absorption (CXL-WA) as an Adjuvant Therapy in the Management of Aspergillus niger Keratitis. Case Rep Ophthalmol Med 2018; 2018: 4856019 doi:10.1155/2018/4856019
    CrossrefPubMedGoogle Scholar
  • 48 Erdem E, Harbiyeli II, Boral H. et al. Corneal Collagen Cross-Linking for the Management of Mycotic Keratitis. Mycopathologia 2018; 183: 521-527
    CrossrefPubMedGoogle Scholar
  • 49 Li Z, Jhanji V, Tao X. et al. Riboflavin/ultravoilet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol 2013; 97: 669-671
    CrossrefPubMedGoogle Scholar
  • 50 Chen Y, Yang W, Gao M. et al. Experimental study on cryotherapy for fungal corneal ulcer. BMC Ophthalmol 2015; 15: 29 doi:10.1186/s12886-015-0011-5
    CrossrefPubMedGoogle Scholar
  • 51 Duncan JK, Chen Y, Belin MW. et al. Excisional keratectomy combined with focal cryotherapy and amniotic membrane inlay for recalcitrant filamentary fungal keratitis: A retrospective comparative clinical data analysis. Exp Ther Med 2016; 12: 3014-3020
    CrossrefPubMedGoogle Scholar
  • 52 Kim HJ, Lim HR, Koh JW. Cryotherapy on Refractory Fungal Corneal Ulcer: A Case Report. J Korean Ophthalmol Soc 2017; 58: 1194
    CrossrefGoogle Scholar
  • 53 Fili S, Schilde T, Perdikakis G. et al. Two Cases of Keratomycosis Caused by Fusarium Solani: Therapeutic Management. J Eye Cataract Surg 2016; DOI: 10.21767/2471-8300.100009.
    CrossrefGoogle Scholar
  • 54 Kocluk Y, Cubuk M, Sukgen E. et al. Early Therapeutic Penetrating Keratoplasty for Fungal Keratitis. J Immunol Clin Microbiol 2016; 1: 18 doi:10.5455/jicm.3.20160510
    CrossrefGoogle Scholar
  • 55 Xie L, Dong X, Shi W. Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol 2001; 85: 1070-1074
    CrossrefPubMedGoogle Scholar
  • 56 Li C, Zhao GQ, Che CY. et al. Effect of corneal graft diameter on therapeutic penetrating keratoplasty for fungal keratitis. Int J Ophthalmol 2012; 5: 698-703 doi:10.3980/j.issn.2222-3959.2012.06.09
    CrossrefPubMedGoogle Scholar
  • 57 Perry HD, Doshi SJ, Donnenfeld ED. et al. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002; 21: 161-163
    CrossrefPubMedGoogle Scholar
  • 58 Pandit RT. Antifungal effects of cyclosporine A. Cornea 2003; 22: 92-93
    PubMedGoogle Scholar
  • 59 Zhong J, Peng L, Wang B. et al. Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis. Mol Vis 2018; 24: 187-200
    PubMedGoogle Scholar